Click on the links below to view active TRND projects:
-
Research
-
- Funding & Notices
-
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Stem Cell Translation Laboratory
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- A Translational Approach to Addressing COVID-19
- Antiviral Program for Pandemics
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes
- Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey
- National COVID Cohort Collaborative (N3C)
- The Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (BGTC)
- NIH Common Fund Programs
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Functional Genomics Lab
- Therapeutics for Rare and Neglected Diseases (TRND)
- About NCATS
Active TRND Projects
Contact
Gene Therapy Advances to Clinical Trial
NCATS and Duke University scientists help advance a gene therapy for Pompe into clinical testing for the first time. - News & Media
- Funding & Notices
-